Cargando…
Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar
Biosimilars are replacing originator compounds due to their similar effectiveness, safety and pharmacokinetics. Our objective was to compare the differences in pharmacokinetics and clinical outcomes between the originator infliximab (Ifx) and the biosimilar CT-P13 in a patient cohort with inflammato...
Autores principales: | Martínez-Feito, Ana, Bravo-Gallego, Luz Yadira, Hernández-Breijo, Borja, Diez, Jesús, García-Ramirez, Laura, Jaquotot, Marta, Plasencia-Rodríguez, Chamaida, Nozal, Pilar, Mezcua, Araceli, Martín- Arranz, María Dolores, Pascual-Salcedo, Dora |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555902/ https://www.ncbi.nlm.nih.gov/pubmed/33051546 http://dx.doi.org/10.1038/s41598-020-74235-1 |
Ejemplares similares
-
BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
por: Hernández-Breijo, Borja, et al.
Publicado: (2021) -
Methotrexate Reduces the Probability of Discontinuation of TNF Inhibitors in Seropositive Patients With Rheumatoid Arthritis. A Real-World Data Analysis
por: Hernández-Breijo, Borja, et al.
Publicado: (2021) -
Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis
por: Hernández-Breijo, Borja, et al.
Publicado: (2022) -
Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions
por: Plasencia, Chamaida, et al.
Publicado: (2015) -
Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis
por: Hernández-Breijo, Borja, et al.
Publicado: (2019)